NICE guidance (NG28) recommends individualised monitoring plans, structured patient education, and 36 monthly HbA1c reviews to optimise GLP-1 therapy and ensure safe diabetes management
Tesamorelin preferentially reduces visceral fat without significantly affecting subcutaneous fat
This novel treatment, nearing Phase 1 clinical trials, could help prevent weight regain post-GLP-1 analogue use by mimicking the incretin hormone to suppress appetite and regulate blood sugar, thus aiding in the management of obesity and diabetes
SSRIs are recommended as first-line pharmacological treatment for depression and generalised anxiety disorder (GAD) in adults, in line with NICE guidelines (NG222 and CG113)
The cardiovascular phenomenon of endothelial dysfunction involves a series of structural and functional abnormalities, including abnormal secretory capacity and properties of the endothelium and impaired vascular tone, as well as an impaired endothelial barrier function
The average weight loss per month on GLP-1 medications improves significantly with consistent physical activity
